Literature DB >> 27330020

Treatment of human immunodeficiency virus-related peripheral neuropathy with Scrambler Therapy: a case report.

Thomas J Smith1, Paul Auwaerter2, Amy Knowlton3, Deanna Saylor4, Justin McArthur4.   

Abstract

Peripheral neuropathy is one of the most common neurological complications of HIV infection with a 30-60% lifetime prevalence. Newer HIV drugs cause less peripheral neuropathy, but patients are now living long enough to develop concomitant diabetes-related, vascular-related, and chemotherapy-related neuropathy so it continues as a major debilitating issue. Recent national CDC guidelines have stressed the importance of non-opioid therapies, especially in this population that may have had drug abuse problems. We treated a 52-year-old man who had severe disabling classic peripheral neuropathy since 1998 with Scrambler Therapy (Calmare), an FDA-cleared peripheral non-invasive neuromodulation device. His pain rapidly improved, as did his motor and sensory function, with just four 45-min treatments, and he was able to come off opioids for the first time in years. When his pain returned six months later, only two treatments were needed to resolve it. This represents the first published use of this novel, inexpensive, and non-invasive pain modality in HIV peripheral neuropathy, and should engender further trials.

Entities:  

Keywords:  HIV-associated neuropathy; neuromodulation; neuropathic pain; scrambler therapy

Mesh:

Year:  2016        PMID: 27330020     DOI: 10.1177/0956462416656688

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  8 in total

1.  Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial.

Authors:  Charles Loprinzi; Jennifer G Le-Rademacher; Neil Majithia; Ryan P McMurray; Carrie R O'Neill; Markus A Bendel; Andreas Beutler; Daniel H Lachance; Andrea Cheville; David M Strick; David F Black; Jon C Tilburt; Thomas J Smith
Journal:  Support Care Cancer       Date:  2019-06-17       Impact factor: 3.603

2.  HIV-related Neuropathy: Pathophysiology, Treatment and Challenges.

Authors:  Noushin Jazebi; Chad Evans; Hima S Kadaru; Divya Kompella; Mukaila Raji; Felix Fang; Miguel Pappolla; Shao-Jun Tang; Jin Mo Chung; Bruce Hammock; Xiang Fang
Journal:  J Neurol Exp Neurosci       Date:  2021-02-06

Review 3.  Neurologic Complications of Human Immunodeficiency Virus Infection.

Authors:  Deanna Saylor
Journal:  Continuum (Minneap Minn)       Date:  2018-10

4.  Scrambler therapy improves pain in neuromyelitis optica: A randomized controlled trial.

Authors:  Maureen A Mealy; Sharon L Kozachik; Lawrence J Cook; Lauren Totonis; Ruth Andrea Salazar; Jerilyn K Allen; Marie T Nolan; Thomas J Smith; Michael Levy
Journal:  Neurology       Date:  2020-04-08       Impact factor: 9.910

Review 5.  The role of human dopamine transporter in NeuroAIDS.

Authors:  Jun Zhu; Subramaniam Ananthan; Chang-Guo Zhan
Journal:  Pharmacol Ther       Date:  2017-10-05       Impact factor: 12.310

Review 6.  Inside the Scrambler Therapy, a Noninvasive Treatment of Chronic Neuropathic and Cancer Pain: From the Gate Control Theory to the Active Principle of Information.

Authors:  Giuseppe Marineo
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

7.  Successful Treatment of Scar Pain with Scrambler Therapy.

Authors:  Mark Yarchoan; Jarushka Naidoo; Thomas J Smith
Journal:  Cureus       Date:  2019-10-14

8.  Scrambler Therapy for the Treatment of Pain in Schwannomatosis.

Authors:  Tyler Murphy; Michael Erdek; Thomas J Smith
Journal:  Cureus       Date:  2022-03-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.